CSL (OTCMKTS:CSLLY) Shares Down 0.5% – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) dropped 0.5% on Tuesday . The stock traded as low as $21.52 and last traded at $21.68. Approximately 796,933 shares changed hands during trading, an increase of 79% from the average session volume of 445,994 shares. The stock had previously closed at $21.79.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CSLLY. Citigroup lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Zacks Research lowered CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, CSL has a consensus rating of “Reduce”.

CSL Trading Down 0.5%

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The company’s 50-day moving average is $19.14 and its two-hundred day moving average is $35.02.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.